Allergy/Asthma News

Enrollment has been completed in a phase 2 clinical trial for the evaluation of bempikibart as a treatment for adults with persistent, moderate to severe atopic dermatitis, Q32 Bio announced in a press release.

Gut microbiomes in children with food allergy may differ from those without food allergy, with fewer differences seen in younger children, according to a study published in Annals of Allergy, Asthma and Immunology.

Patients with allergic rhinitis experience a greater number and diversity of symptoms when they have increasing numbers of sensitizations, according to a study published in Annals of Allergy, Asthma & Immunology.

The FDA has approved Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older, Arcutis announced in a press release.

Bloomberg Philanthropies announced that it has donated $1 billion to make Johns Hopkins University’s medical school free for most of its students seeking an MD.

The FDA is working to finalize an action letter regarding Arcutis’ supplemental new drug application for roflumilast cream 0.15% indicated for atopic dermatitis, the company announced in a press release.

The FDA issued a warning against Bimbo Bakeries USA, which includes brands such as Sara Lee and Brownberry among others, on June 25 over incorrect allergy warning labels.

A dry powder epinephrine delivered via a nasal spray yielded drug exposures that were equal to or higher than those achieved through autoinjector in a canine model, according to the results of a study performed by Belhaven Biopharma.

Dupilumab treatment was associated with the reduced risk for atopic march progression in pediatric and adolescent patients with atopic dermatitis, according to a study.

A picture-based scorecard with multiple skin tones facilitated the assessment of atopic dermatitis among infants, according to a study published in Annals of Allergy, Asthma & Immunology.